AIM
ENTA icon

Advantage Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Advantage Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$62K Sell
1,037
-301
-22% -$22.4K 0.05% 297
2019
Q2 		$113K Sell
1,338
-108
-7% -$9.71K 0.09% 217
2019
Q1 		$138K Hold
1,446
– – 0.11% 187
2018
Q4 		$102K Hold
1,446
– – 0.08% 233
2018
Q3 		$124K Buy
+1,446
New +$145K 0.08% 231

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Advantage Investment Management's ENTA Position: Q3 2019 in Review

Advantage Investment Management reduced its Enanta Pharmaceuticals (ENTA) stake by 22% in Q3 2019, selling an estimated $22.4K and leaving 1,037 shares worth $62K. The position accounts for 0.05% of the portfolio, ranked #297.

Advantage Investment Management first reported a position in ENTA in Q3 2018 and has held it in 5 quarters since. The position peaked at $138K in Q1 2019. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

  • Advantage Investment Management held 1,037 shares of Enanta Pharmaceuticals worth $62K as of Q3 2019.
  • Advantage Investment Management sold 301 Enanta Pharmaceuticals shares in Q3 2019, an estimated $22.4K.
  • Enanta Pharmaceuticals made up 0.05% of Advantage Investment Management's portfolio in Q3 2019, its #297 holding.
  • Advantage Investment Management first reported a position in Enanta Pharmaceuticals in Q3 2018 and has held it in 5 quarters since.
  • Advantage Investment Management's Enanta Pharmaceuticals position peaked at $138K in Q1 2019.
  • 176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.